Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care
- 24 February 2012
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 20 (11) , 2829-2836
Abstract
Palliative sedation (PS) has been defined as the use of sedative medications to relieve intolerable suffering from refractory symptoms by a reduction in patient consciousness. It is sometimes necessary in end-of-life care when patients present refractory symptoms. We investigated PS for refractory symptoms in different hospice casemixes in order to (1) assess clinical decision-making, (2) monitor the practice of PS, and (3) examine the impact of PS on survival. This observational longitudinal cohort study was conducted over a period of 9 months on 327 patients consecutively admitted to two 11-bed Italian hospices (A and B) with different casemixes in terms of median patient age (hospice A, 66 years vs. hospice B, 73 years; P = 0.005), mean duration of hospice stay (hospice A, 13.5 days vs. hospice B, 18.3 days; P = 0.005), and death rate (hospice A, 57.2% vs. hospice B, 89.9%; P < 0.0001). PS was monitored using the Richmond Agitation–Sedation Scale (RASS). Sedated patients constituted 22% of the total admissions and 31.9% of deceased patients, which did not prove to be significantly different in the two hospices after adjustment for casemix. Patient involvement in clinical decision-making about sedation was significantly higher in hospice B (59.3% vs. 24.4%; P = 0.007). Family involvement was 100% in both hospices. The maximum level of sedation (RASS, −5) was necessary in only 58.3% of sedated patients. Average duration of sedation was similar in the two hospices (32.2 h [range, 2.5–253.0]). Overall survival in sedated and nonsedated patients was superimposable, with a trend in favor of sedated patients. PS represents a highly reproducible clinical intervention with its own indications, assessment methodologies, procedures, and results. It does not have a detrimental effect on survival.Keywords
This publication has 26 references indexed in Scilit:
- National Hospice and Palliative Care Organization (NHPCO) Position Statement and Commentary on the Use of Palliative Sedation in Imminently Dying Terminally Ill PatientsJournal of Pain and Symptom Management, 2010
- European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive programAnnals of Oncology, 2009
- Palliative sedation therapy does not hasten death: results from a prospective multicenter studyAnnals of Oncology, 2009
- Medically assisted hydration for adult palliative care patients2008
- Palliative Sedation as Part of a Continuum of Palliative CareJournal of Palliative Medicine, 2008
- Continuous Deep Sedation: Physicians' Experiences in Six European CountriesJournal of Pain and Symptom Management, 2006
- Efficacy and Safety of Palliative Sedation Therapy: A Multicenter, Prospective, Observational Study Conducted on Specialized Palliative Care Units in JapanJournal of Pain and Symptom Management, 2005
- End-of-life decision-making in six European countries: descriptive studyThe Lancet, 2003
- Practices and Attitudes of Japanese Oncologists and Palliative Care Physicians Concerning Terminal Sedation: A Nationwide SurveyJournal of Clinical Oncology, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958